App-Quantinova.ai

ASSESSING ANTIBODY STATUS FOR SARS-CoV-2 IN PEOPLE WITH CORONAVIRUS INFECTION: A TIME COURSE STUDY IN PEOPLE WITH AUTOIMMUNE CONDITIONS

K. Biddle - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

ASSESSING THE CHARACTERISTICS AND MANAGEMENT OF KNEE OSTEOARTHRITIS PATIENTS WITH HYPERTENSION BY CLINICIAN SPECIALITY

D. Baldock - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1)

M. Garrido-Cumbrera - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

ASSOCIATION BETWEEN BIOMARKERS AND THERAPEUTIC PATHWAY IN PATIENTS WITH SLE

S. U. Hassan - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Cyclophosphamide

ASSOCIATION BETWEEN INDIVIDUAL AND COUNTRY-LEVEL SOCIOECONOMIC FACTORS AND HEALTH OUTCOMES IN AXIAL AND PERIPHERAL SPONDYLOARTHRITIS: ANALYSIS OF THE ASASPERSPA STUDY

D. Capelusnik - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Peripheral spondyloarthritis

N/A

ASSOCIATION BETWEEN INDIVIDUAL AND COUNTRY-LEVEL SOCIOECONOMIC FACTORS AND WORK PARTICIPATION IN PERIPHERAL AND AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE ASAS perSpA Study

S. S. Zhao - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

ASSOCIATION BETWEEN RA DISEASE ACTIVITY AND TOOTH LOSS: RESULTS OF TWO NATIONAL COHORTS

K. Albrecht - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

ASSOCIATION OF HLA-DRB1 HAPLOTYPES WITH CARDIOVASCULAR MORTALITY IN INFLAMMATORY POLYARTHRITIS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER

S. Sharma - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE

J. Sparks - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

Glucocorticoid

AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY

J. M. Van Laar - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Prednisolone

BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITIS

P. C. Taylor - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

BARRIERS AND FACILITATORS RELATED TO SELF-MANAGEMENT OF SHOULDER PAIN: A SYSTEMATIC REVIEW AND QUALITATIVE SYNTHESIS

A. O�shea - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

BELFAST TRUST EXPERIENCE OF IDIOPATHIC INFLAMMATORY MYOPATHIES

S. Loughrey - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

BELIMUMAB AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DSDNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

M. Shipa - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prednisolone

BILAG-2004 INDEX ACTIVE DISEASE PREDICTS DEVELOPMENT OF DAMAGE

C. S. Yee - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

N/A

BILAG-2004 LDA AND BST LDA ARE VALID TREAT TO TARGET IN SLE

C. S. Yee - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

D. Van der Heijde - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

bimekizumab

BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY

L. C. Coates - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

bimekizumab

BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

X. Baraliakos - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

bimekizumab

BLOCKING ROR2 IMPROVES CARTILAGE INTEGRITY AND PROVIDES PAIN RELIEF IN OSTEOARTHRITIS

A. S. Thorup - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

L-Tyrosine

Filters

45280 Abstracts